320-51-4Sorafenib Impurity C

● In Stock

Catalogue No.:	VE005960
CAS No.:	320-51-4
Mol. Formula:	C7H5ClF3N
Mol. Weight:	195.57 g/mol

Request a quote

Add to RFQ list

Additional information on CAS 320-51-4

Parent drug

Regorafenib / Sorafenib

IUPAC Name

4-Chloro-3-(trifluoromethyl)-benzenamine

Pharmacopoeial Synonyms

Regorafenib FP Impurity B/5-Amino-2-chlorobenzotrifluoride

Other Synonyms

4-Chloro-3-(trifluoromethyl)aniline)

Smiles

C1=CC(=C(C=C1N)C(F)(F)F)Cl

InChI

InChI=1S/C7H5ClF3N/c8-6-2-1-4(12)3-5(6)7(9,10)11/h1-3H,12H2

Shipping Condition

Ambient Temperature

Characterization Data (Included)

HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, and Structure Elucidation Report (SER).

Additional Characterization Data

QNMR, D2O Exchange, 13C NMR, 13C APT, COSY NMR, NOESY NMR, 15N NMR, HSQC NMR, HMQC NMR, and HMBC NMR. These are available upon request and may be free or subject to additional charges.

Description

Also known as 5-Amino-2-chlorobenzotrifluoride or 4-Chloro-3-(trifluoromethyl)aniline, it is an impurity present in Sorafenib which is a potent oral multi-kinase inhibitor used for cancer treatment. It exhibits anti-angiogenic and anti-tumor activity by suppressing the autophosphorylation of several cell surface tyrosine kinases involved in controlling cell growth.

References

Johnsirani, P., et al. “LC-ESI-QTOF-MS Analysis Utilizing Gas-Phase Fragmentation Reactions Subjected to ESI-IS-CID and ESI-CID-MS/MS Conditions to Study the Degradation Behaviour of Sorafenib Tosylate: NMR and in Vitro Cytotoxicity and Apoptosis Detection Studies of Hydrolytic Degradation Products.” Journal of Pharmaceutical and Biomedical Analysis, vol. 177, Jan. 2020, p. 112881, https://doi.org/10.1016/j.jpba.2019.112881. ?